These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 22920226)

  • 1. Sponsors' participation in conduct and reporting of industry trials: a descriptive study.
    Lundh A; Krogsbøll LT; Gøtzsche PC
    Trials; 2012 Aug; 13():146. PubMed ID: 22920226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.
    Tuech JJ; Moutel G; Pessaux P; Thoma V; Schraub S; Herve C
    Eur J Cancer; 2005 Oct; 41(15):2237-40. PubMed ID: 16214044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study.
    Lundh A; Barbateskovic M; Hróbjartsson A; Gøtzsche PC
    PLoS Med; 2010 Oct; 7(10):e1000354. PubMed ID: 21048986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dependability of results in conference abstracts of randomized controlled trials in ophthalmology and author financial conflicts of interest as a factor associated with full publication.
    Saldanha IJ; Scherer RW; Rodriguez-Barraquer I; Jampel HD; Dickersin K
    Trials; 2016 Apr; 17(1):213. PubMed ID: 27113767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Industry sponsorship and authorship of clinical trials over 20 years.
    Buchkowsky SS; Jewesson PJ
    Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial conflicts of interest and their association with outcome and quality of fibromyalgia drug therapy randomized controlled trials.
    Pang WK; Yeter KC; Torralba KD; Spencer HJ; Khan NA
    Int J Rheum Dis; 2015 Jul; 18(6):606-15. PubMed ID: 26012523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
    Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
    Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study.
    Turner K; Carboni-Jiménez A; Benea C; Elder K; Levis B; Boruff J; Roseman M; Bero L; Lexchin J; Turner EH; Benedetti A; Thombs BD
    BMJ Open; 2020 May; 10(5):e035633. PubMed ID: 32398334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor.
    Flacco ME; Manzoli L; Boccia S; Capasso L; Aleksovska K; Rosso A; Scaioli G; De Vito C; Siliquini R; Villari P; Ioannidis JP
    J Clin Epidemiol; 2015 Jul; 68(7):811-20. PubMed ID: 25748073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research funding, conflicts of interest, and the meta-methodology of public relations.
    Rampton S; Stauber J
    Public Health Rep; 2002; 117(4):331-9. PubMed ID: 12477914
    [No Abstract]   [Full Text] [Related]  

  • 12. Industry sponsorship and research outcome.
    Lundh A; Sismondo S; Lexchin J; Busuioc OA; Bero L
    Cochrane Database Syst Rev; 2012 Dec; 12():MR000033. PubMed ID: 23235689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.
    Matcham J; Julious S; Pyke S; O'Kelly M; Todd S; Seldrup J; Day S
    Pharm Stat; 2011; 10(1):70-3. PubMed ID: 20187020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study.
    Clifford TJ; Barrowman NJ; Moher D
    BMC Health Serv Res; 2002 Sep; 2(1):18. PubMed ID: 12213183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?
    Golder S; Loke YK
    Br J Clin Pharmacol; 2008 Dec; 66(6):767-73. PubMed ID: 18754841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Authorship selection in industry-sponsored publications of dermatology clinical trials.
    Tauber M; Paul C
    Br J Dermatol; 2017 Jun; 176(6):1669-1671. PubMed ID: 28303566
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors.
    Rasmussen K; Bero L; Redberg R; Gøtzsche PC; Lundh A
    BMJ; 2018 Oct; 363():k3654. PubMed ID: 30282703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.
    Safer DJ
    J Nerv Ment Dis; 2002 Sep; 190(9):583-92. PubMed ID: 12357091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: a systematic review.
    Mugambi MN; Musekiwa A; Lombard M; Young T; Blaauw R
    BMC Med Res Methodol; 2013 Nov; 13():137. PubMed ID: 24219082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.